Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ECI 830

Next Previous
Drug Profile

ECI 830

Alternative Names: ECI-830

Latest Information Update: 03 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Cyclin-dependent kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II HER2 negative breast cancer; HER2 positive breast cancer; Solid tumours

Most Recent Events

  • 03 Apr 2025 Phase-I/II clinical trials in HER2-negative-breast-cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable) in South Korea, Japan, Israel, Canada, Australia, USA (unspecified route) (NCT06726148)
  • 03 Apr 2025 Phase-I/II clinical trials in HER2-negative-breast-cancer (Monotherapy, Second-line therapy or greater, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in South Korea, Japan, Israel, Canada, Australia, USA (unspecified route) (NCT06726148)
  • 03 Apr 2025 Phase-I/II clinical trials in HER2-positive-breast-cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in South Korea, Japan, Israel, Canada, Australia, USA (unspecified route) (NCT06726148)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top